PMID- 38023696
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 2380-6761 (Print)
IS  - 2380-6761 (Electronic)
IS  - 2380-6761 (Linking)
VI  - 8
IP  - 6
DP  - 2023 Nov
TI  - Membrane fusogenic nanoparticle-based HLA-peptide-addressing universal T cell 
      receptor-engineered T (HAUL TCR-T) cell therapy in solid tumor.
PG  - e10585
LID - 10.1002/btm2.10585 [doi]
LID - e10585
AB  - T cell receptor-engineered T (TCR-T) cell therapy has demonstrated therapeutic 
      effects in basic research and clinical trials for treating solid tumors. Due to 
      the peptide-dependent recognition and the human leukocyte antigen 
      (HLA)-restriction, TCR-T cell therapy is generally custom designed to target 
      individual antigens. The lack of suitable universal targets for tumor cells 
      significantly limits its clinical applications. Establishing a universal TCR-T 
      treatment strategy is of great significance. This study designed and evaluated 
      the HLA-peptide-addressing universal (HAUL) TCR-T cell therapy based on 
      HLA-peptide (pHLA) loaded membrance fusogenic deliver system. The pHLA-NP-based 
      tumor cell membrane modification technology can transfer the pHLA onto the 
      surface of tumor cells through membrane fusogenic nanoparticles. Then tumor cells 
      are recognized and killed by TCR-T cells specifically. The HAUL TCR-T cell 
      therapy technology is a universal technology that enables tumor cells to be 
      identified and killed by specific TCR-T cells, regardless of the HLA typing of 
      tumor cells.
CI  - (c) 2023 The Authors. Bioengineering & Translational Medicine published by Wiley 
      Periodicals LLC on behalf of American Institute of Chemical Engineers.
FAU - Xu, Ruihan
AU  - Xu R
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital The Affiliated 
      Hospital of Nanjing University Medical School Nanjing China.
FAU - Wang, Qin
AU  - Wang Q
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital The Affiliated 
      Hospital of Nanjing University Medical School Nanjing China.
FAU - Zhu, Junmeng
AU  - Zhu J
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital The Affiliated 
      Hospital of Nanjing University Medical School Nanjing China.
FAU - Bei, Yuncheng
AU  - Bei Y
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital The Affiliated 
      Hospital of Nanjing University Medical School Nanjing China.
FAU - Chu, Yanhong
AU  - Chu Y
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital The Affiliated 
      Hospital of Nanjing University Medical School Nanjing China.
FAU - Sun, Zhichen
AU  - Sun Z
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital The Affiliated 
      Hospital of Nanjing University Medical School Nanjing China.
FAU - Du, Shiyao
AU  - Du S
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital The Affiliated 
      Hospital of Nanjing University Medical School Nanjing China.
FAU - Zhou, Shujuan
AU  - Zhou S
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital The Affiliated 
      Hospital of Nanjing University Medical School Nanjing China.
FAU - Ding, Naiqing
AU  - Ding N
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital The Affiliated 
      Hospital of Nanjing University Medical School Nanjing China.
FAU - Meng, Fanyan
AU  - Meng F
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital The Affiliated 
      Hospital of Nanjing University Medical School Nanjing China.
FAU - Liu, Baorui
AU  - Liu B
AUID- ORCID: 0000-0002-2539-7732
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital The Affiliated 
      Hospital of Nanjing University Medical School Nanjing China.
LA  - eng
PT  - Journal Article
DEP - 20230807
PL  - United States
TA  - Bioeng Transl Med
JT  - Bioengineering & translational medicine
JID - 101689146
PMC - PMC10658479
OTO - NOTNLM
OT  - HLA-peptide complex
OT  - TCR-T cell therapy
OT  - membrane fusogenic nanoparticles
OT  - solid tumors
OT  - tumor cell membrane modification
COIS- The authors declare no conflicts of interest.
EDAT- 2023/11/29 18:41
MHDA- 2023/11/29 18:42
PMCR- 2023/08/07
CRDT- 2023/11/29 15:53
PHST- 2023/01/10 00:00 [received]
PHST- 2023/06/12 00:00 [revised]
PHST- 2023/06/14 00:00 [accepted]
PHST- 2023/11/29 18:42 [medline]
PHST- 2023/11/29 18:41 [pubmed]
PHST- 2023/11/29 15:53 [entrez]
PHST- 2023/08/07 00:00 [pmc-release]
AID - BTM210585 [pii]
AID - 10.1002/btm2.10585 [doi]
PST - epublish
SO  - Bioeng Transl Med. 2023 Aug 7;8(6):e10585. doi: 10.1002/btm2.10585. eCollection 
      2023 Nov.